Rakuten Securities Inc. Sells 785 Shares of Johnson & Johnson (NYSE:JNJ)

Rakuten Securities Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 52.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 698 shares of the company’s stock after selling 785 shares during the quarter. Rakuten Securities Inc.’s holdings in Johnson & Johnson were worth $113,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. bought a new position in Johnson & Johnson during the 1st quarter worth $765,000. Empowered Funds LLC lifted its stake in shares of Johnson & Johnson by 46.7% in the first quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock worth $16,015,000 after acquiring an additional 32,244 shares during the period. Concurrent Investment Advisors LLC boosted its holdings in Johnson & Johnson by 0.8% in the first quarter. Concurrent Investment Advisors LLC now owns 72,368 shares of the company’s stock valued at $11,448,000 after acquiring an additional 608 shares during the last quarter. Bey Douglas LLC raised its holdings in Johnson & Johnson by 4.6% during the 1st quarter. Bey Douglas LLC now owns 1,826 shares of the company’s stock worth $289,000 after purchasing an additional 81 shares during the last quarter. Finally, Nixon Peabody Trust Co. lifted its position in shares of Johnson & Johnson by 4.6% in the 1st quarter. Nixon Peabody Trust Co. now owns 111,636 shares of the company’s stock worth $17,660,000 after purchasing an additional 4,942 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on JNJ shares. Royal Bank of Canada upped their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Sanford C. Bernstein increased their price target on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Guggenheim lifted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Finally, Morgan Stanley increased their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.00.

Johnson & Johnson Stock Down 1.5 %

Shares of NYSE:JNJ opened at $152.64 on Wednesday. The firm has a market capitalization of $367.50 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 2.75 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The firm has a fifty day moving average of $162.39 and a 200 day moving average of $155.97.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the previous year, the company posted $2.66 EPS. Johnson & Johnson’s quarterly revenue was up 5.2% compared to the same quarter last year. As a group, research analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.25%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.